NEW YORK (GenomeWeb News) — GenomeQuest said today it is licensing its sequence search technology to Migenix, a Vancouver, BC-based drug developer.
The company, formerly known as Gene-IT, said Migenix will use its GenomeQuest product in its clinical programs, which include drug candidates for hepatitis C, catheter-related infections, and dermatological diseases.
GenomeQuest said its application is used by biologists evaluating gene sequences and by patent lawyers who are considering issues of patentability of certain sequences.
The technology comprises close to 50 million patented sequences, the company said.
Financial terms of the agreement were not released.
Gene-IT said last week it has changed its name to GenomeQuest.